Jaumdally Rumi J, Varma Chetan, MacFadyen Robert J, Lip Gregory Y H
Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK.
J Thromb Thrombolysis. 2007 Jun;23(3):189-94. doi: 10.1007/s11239-006-9048-x. Epub 2007 Jan 13.
Non-ionic low osmolar contrast agents are widely used during coronary angiography. As these agents cause activation of thrombotic pathways in vitro, this may have potentially significant clinical impact. However, limited evidence exists as to their in vivo effects from selective coronary cannulation.
We initially performed an in vitro experiment to assess the effect of serial contrast (Iomeprol 300, Bracco) dilution on platelet indices [mean platelet count (MPC), platelet volume (MPV), platelet granularity (MPG)]. The in vivo effect of contrast injection on platelet activation markers [soluble P-selectin (sPsel), soluble CD40 ligand (sCD40L)], MPC, MPV, MPG, haemoglobin and haematocrit was subsequently determined in 35 patients (mean age 58 +/- 11; 22 males) undergoing cardiac catheterisaton.
No significant in vitro effect of contrast on MPC or MPV was seen but there was a significant increase in MPG (p = 0.40, 0.10 and 0.01, respectively). In the in vivo study, there was a reduction in mean haemoglobin and haematocrit levels, suggesting an average increase in plasma volume of 6.5 +/- 5.8%. The in vivo effect of Iomeprol was associated with an unadjusted reduction in sPsel concentrations (p = 0.04) and MPV (p < 0.05), with denser platelets (p < 0.05). There was no difference in MPC or sCD40L concentration (both p = NS). After adjustment for the haemodilution effect, no significant reduction in P-sel levels was seen with contrast (p = 0.27), although the adjusted post-contrast change in MPG (p = 0.01), MPC (p = 0.01) and sCD40L (p < 0.05) levels were significant.
Low osmolar contrast led to a minimal effect on soluble and physical indices of platelets within the coronary artery, primarily due to plasma volume expansion.
非离子型低渗造影剂在冠状动脉造影中广泛应用。由于这些造影剂在体外可激活血栓形成途径,这可能具有潜在的重大临床影响。然而,关于选择性冠状动脉插管后其体内效应的证据有限。
我们首先进行了一项体外实验,以评估连续造影剂(碘普罗胺300,博莱科公司)稀释对血小板指标[平均血小板计数(MPC)、血小板体积(MPV)、血小板颗粒度(MPG)]的影响。随后,在35例接受心脏导管插入术的患者(平均年龄58±11岁;22例男性)中,确定了注射造影剂对血小板活化标志物[可溶性P-选择素(sPsel)、可溶性CD40配体(sCD40L)]、MPC、MPV、MPG、血红蛋白和血细胞比容的体内效应。
体外实验中未观察到造影剂对MPC或MPV有显著影响,但MPG有显著增加(分别为p = 0.40、0.10和0.01)。在体内研究中,平均血红蛋白和血细胞比容水平降低,提示血浆量平均增加6.5±5.8%。碘普罗胺的体内效应与未校正的sPsel浓度降低(p = 0.04)和MPV降低(p < 0.05)相关,血小板密度增加(p < 0.05)。MPC或sCD40L浓度无差异(p值均为无显著性差异)。校正血液稀释效应后,造影剂注射后P-选择素水平无显著降低(p = 0.27),尽管校正后造影剂注射后MPG(p = 0.01)、MPC(p = 0.01)和sCD40L(p < 0.05)水平的变化具有显著性。
低渗造影剂对冠状动脉内血小板的可溶性和物理指标影响极小,主要是由于血浆量扩张所致。